FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139241036> ?p ?o ?g. }

• W2139241036 endingPage "1567" @default.
• W2139241036 startingPage "1560" @default.
• W2139241036 abstract "BackgroundMetastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of mCRC to assess safety and pharmacokinetics (primary objectives) and tumor response (secondary objective).Patients and methodsForty-five patients were treated every 2 weeks with 5-fluorouracil 400 mg/m2 bolus then 2400 mg/m2 over 46 h, folinic acid 400 mg/m2, and either oxaliplatin 85 mg/m2 or irinotecan 180 mg/m2. On days 4–10, patients received regorafenib 160 mg orally once daily.ResultsThe median duration of treatment was 108 (range 2–345 days). Treatment was stopped for adverse events or death (17 patients), disease progression (11 patients), and consent withdrawal or investigator decision (11 patients). Six patients remained on regorafenib at data cutoff (two without chemotherapy). Drug-related adverse events occurred in 44 patients [grade ≥3 in 32 patients: mostly neutropenia (17 patients) and leukopenia, hand–foot skin reaction, and hypophosphatemia (four patients each)]. Thirty-three patients achieved disease control (partial response or stable disease) for a median of 126 (range 42–281 days).ConclusionRegorafenib had acceptable tolerability in combination with chemotherapy, with increased exposure of irinotecan and SN-38 but no significant effect on 5-fluorouracil or oxaliplatin pharmacokinetics." @default.
• W2139241036 created "2016-06-24" @default.
• W2139241036 creator A5007121420 @default.
• W2139241036 creator A5018436714 @default.
• W2139241036 creator A5019710731 @default.
• W2139241036 creator A5027572658 @default.
• W2139241036 creator A5035767951 @default.
• W2139241036 creator A5040836871 @default.
• W2139241036 creator A5042105483 @default.
• W2139241036 creator A5046556178 @default.
• W2139241036 creator A5047241292 @default.
• W2139241036 creator A5059144177 @default.
• W2139241036 creator A5065202186 @default.
• W2139241036 creator A5070529188 @default.
• W2139241036 creator A5073459990 @default.
• W2139241036 creator A5081249304 @default.
• W2139241036 date "2013-06-01" @default.
• W2139241036 modified "2023-10-11" @default.
• W2139241036 title "Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study" @default.
• W2139241036 cites W1968209756 @default.
• W2139241036 cites W1968384808 @default.
• W2139241036 cites W2006202974 @default.
• W2139241036 cites W2007485357 @default.
• W2139241036 cites W2012708129 @default.
• W2139241036 cites W2030158769 @default.
• W2139241036 cites W2069158883 @default.
• W2139241036 cites W2116372652 @default.
• W2139241036 cites W2118117088 @default.
• W2139241036 cites W2125763124 @default.
• W2139241036 cites W2127640925 @default.
• W2139241036 cites W2128447158 @default.
• W2139241036 cites W2130583782 @default.
• W2139241036 cites W2131183275 @default.
• W2139241036 cites W2133399075 @default.
• W2139241036 cites W2140043667 @default.
• W2139241036 cites W2143036717 @default.
• W2139241036 cites W2143980344 @default.
• W2139241036 cites W2147834058 @default.
• W2139241036 cites W2148218538 @default.
• W2139241036 cites W2151820488 @default.
• W2139241036 cites W2152004983 @default.
• W2139241036 cites W2157769714 @default.
• W2139241036 cites W2161593277 @default.
• W2139241036 cites W2165741055 @default.
• W2139241036 cites W2561067672 @default.
• W2139241036 doi "https://doi.org/10.1093/annonc/mdt056" @default.
• W2139241036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3660081" @default.
• W2139241036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23493136" @default.
• W2139241036 hasPublicationYear "2013" @default.
• W2139241036 type Work @default.
• W2139241036 sameAs 2139241036 @default.
• W2139241036 citedByCount "79" @default.
• W2139241036 countsByYear W21392410362013 @default.
• W2139241036 countsByYear W21392410362014 @default.
• W2139241036 countsByYear W21392410362015 @default.
• W2139241036 countsByYear W21392410362016 @default.
• W2139241036 countsByYear W21392410362017 @default.
• W2139241036 countsByYear W21392410362018 @default.
• W2139241036 countsByYear W21392410362019 @default.
• W2139241036 countsByYear W21392410362020 @default.
• W2139241036 countsByYear W21392410362021 @default.
• W2139241036 countsByYear W21392410362022 @default.
• W2139241036 countsByYear W21392410362023 @default.
• W2139241036 crossrefType "journal-article" @default.
• W2139241036 hasAuthorship W2139241036A5007121420 @default.
• W2139241036 hasAuthorship W2139241036A5018436714 @default.
• W2139241036 hasAuthorship W2139241036A5019710731 @default.
• W2139241036 hasAuthorship W2139241036A5027572658 @default.
• W2139241036 hasAuthorship W2139241036A5035767951 @default.
• W2139241036 hasAuthorship W2139241036A5040836871 @default.
• W2139241036 hasAuthorship W2139241036A5042105483 @default.
• W2139241036 hasAuthorship W2139241036A5046556178 @default.
• W2139241036 hasAuthorship W2139241036A5047241292 @default.
• W2139241036 hasAuthorship W2139241036A5059144177 @default.
• W2139241036 hasAuthorship W2139241036A5065202186 @default.
• W2139241036 hasAuthorship W2139241036A5070529188 @default.
• W2139241036 hasAuthorship W2139241036A5073459990 @default.
• W2139241036 hasAuthorship W2139241036A5081249304 @default.
• W2139241036 hasBestOaLocation W21392410361 @default.
• W2139241036 hasConcept C121608353 @default.
• W2139241036 hasConcept C126322002 @default.
• W2139241036 hasConcept C141071460 @default.
• W2139241036 hasConcept C197934379 @default.
• W2139241036 hasConcept C2776248978 @default.
• W2139241036 hasConcept C2776694085 @default.
• W2139241036 hasConcept C2776705615 @default.
• W2139241036 hasConcept C2778260052 @default.
• W2139241036 hasConcept C2778375690 @default.
• W2139241036 hasConcept C2779804826 @default.
• W2139241036 hasConcept C2780259306 @default.
• W2139241036 hasConcept C2780456651 @default.
• W2139241036 hasConcept C2780873365 @default.
• W2139241036 hasConcept C2780962732 @default.
• W2139241036 hasConcept C526805850 @default.
• W2139241036 hasConcept C71924100 @default.
• W2139241036 hasConcept C90924648 @default.
• W2139241036 hasConceptScore W2139241036C121608353 @default.
• W2139241036 hasConceptScore W2139241036C126322002 @default.

• next